EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Bond
2015-05-08 / 15:46
Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------
Cytos' bond conversion into equity effective

- 77.49 million shares newly issued in exchange for convertible bonds
- First day of trading of new shares originally scheduled for May 11, 2015 but due to mistake from SIS AG already possible on May 8, 2015
Schlieren (Zurich), Switzerland, May 8, 2015 - Cytos Biotechnology Ltd ("Cytos") today announced that the convertible bond restructuring has been completed with effect as of May 8, 2015. As a result, 77'490'000 shares have been issued on top of the 30'525'276 shares already issued and outstanding. Hence, the total number of shares issued and outstanding now amounts to 108'015'276 shares. All newly issued shares were originally scheduled to be free for trading starting Monday, May 11, 2015 and are equal to those already issued and listed at the SIX Swiss Exchange. However, due to a mistake by SIS AG, certain shares were already possible to trade on May 8, 2015 as per message below.

As announced previously, all claims from the convertible loan note holders are eliminated upon the bonds conversion into equity. As a result, Cytos is free of any debt going forward with immediate effect.
Message from SIS AG:

Quote

Switzerland: Friday, 8 May 2015: De-blocking of a shares Cytos Biotechnology AG, Schlieren:

Due to a technical error the new shares of Cytos Biotechnology, ISIN CH0011025217, resulting from the mandatory conversion 5.75 % Cytos Biotechnology (ISIN CH0029060735) have been de-blocked already today around 9.00 CET, 8 May 2015 instead of 11 May 2015. Realizing the mistake the decision was taken to keep the shares de-blocked.
We apologize for any inconvenience caused and thank you for your understanding.
Yours faithfully
SIX SIS Ltd

Unquote

For further information, please contact: 

Cytos Biotechnology Ltd 
Harry Welten, MBA 
Chief Financial Officer 
Tel: +41 44 733 46 46 
harry.welten@cytos.com 

About Cytos Biotechnology Ltd 

Cytos is a public biopharmaceutical company located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements 
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "will" or "expect" or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

www.cytos.com
End of ad hoc announcement

+++++
Additional features:

Document: http://n.equitystory.com/c/fncls.ssp?u=HONCSADFJY Document title: Cytos_conversion_150508

---------------------------------------------------------------------
2015-05-08 News transmitted by EQS Schweiz AG. www.eqs.com - news archive: http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.
---------------------------------------------------------------------

Language: English Company: Cytos Biotechnology AG Wagistr. 25 8952 Schlieren Switzerland Phone: +41 44 733 4747 Fax: +41 44 733 4740 E-mail: info@cytos.com Internet: www.cytos.com ISIN: CH0011025217, CH0029060735 Valor: - Listed: Regulated Unofficial Market in Berlin, Munich, Stuttgart; Open Market in Frankfurt ; SIX  
 
End of News    EQS Group News-Service  
--------------------------------------------------------------------- 355233 2015-05-08